207
Participants
Start Date
June 27, 2022
Primary Completion Date
September 30, 2025
Study Completion Date
April 30, 2030
Bezuclastinib Tablets (Formulation A)
Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
Bezuclastinib Tablets (Formulation B)
Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
Placebo Tablets
Placebo will be administered orally, once daily continuously for 28-day cycles
Policlinico Universitario Agostino Gemelli, Rome
Royal Prince Alfred Hospital, Camperdown
Antwerp University Hospital (UZA), Edegem
University Hospital Basel, Basel
Royal Adelaide Hospital, Adelaide
University Medical Center Groningen, Groningen
Icahn School of Medicine at Mount Sinai, New York
Charité Universitätsmedizin Berlin, Berlin
Allervie Clinical Research, Glenn Dale
Walter Reed National Military Medical Center, Bethesda
Institute for Asthma and Allergy, Wheaton
Chesapeake Research Center, White Marsh
Fondazione IRCCS Policlinico San Matteo, Pavia
Duke University, Raleigh
Hospital Universitario Ramon y Cajal, Madrid
Medical University of South Carolina, Charleston
Emory University, Atlanta
CHU de Toulouse - Hopital Larrey, Toulouse
Mayo Clinic - Jacksonville, Jacksonville
University of South Florida, Tampa
Innovative Research of West Florida, Clearwater
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola, Bologna
The Ohio State University, Columbus
University of Cincinnati, Cincinnati
University of Michigan, Ann Arbor
Universitaetsklinikum Aachen, AoeR, Aachen
Mayo Clinic- Rochester, Rochester
Rush University, Chicago
Washington University at St. Louis, St Louis
University Medical Centre Mannheim, Mannheim
AP-HP- Hopital Pitie-Salpetriere, Paris
AIR Care, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Metrodora Institute of Technology, West Valley City
Mayo Clinic Arizona, Phoenix
One of a Kind Clinical Research Center, Scottsdale
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
Modena Allergy and Asthma Clinical, La Jolla
Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
Kepler Universitaetsklinikum GmbH, Linz
Medizinische Universitaet Wien, Vienna
CHU Tivoli, La Louvière
St. Michael's Hospital, Toronto
McGill University, Montreal
Fakultni nemocnice Kralovske Vinohrady, Prague
AP-HM - Hopital de la Timone, Marseille
Universitaetsklinikum Hamburg-Eppendorf, Hamburg
Universitätsklinikum Schleswig-Holstein, Kiel
Attikon University General Hospital Athens, Athens
Cork University Hospital, Cork
AOU Policlinico Rodolico San Marco, Catania
Azienda Ospedaliero-Universitaria Careggi, Florence
AUSL della Romagna-Ospedale S.Maria delle Croci, Ravenna
Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento, Verona
Erasmus Rotterdam, Rotterdam
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Gdansk
Samodzielny Publiczny Szpital Kliniczny Nr 1 - Klinika Hematoonkologii i Transplantacji Szpiku, Lublin
Institut Catala d'Oncologia - L'Hospitalet, Barcelona
Instituto de Estudios de Mastocitosis de Castilla La Mancha-Hospital Virgen del Valle, Toledo
Tom Baker Cancer Centre, Calgary
University of Alberta, Edmonton
St. James's Hospital, Dublin
Oslo University Hospital, Oslo
Hospital Universitario Vall d'Hebron, Barcelona
Guy's Hospital, London
Lead Sponsor
Cogent Biosciences, Inc.
INDUSTRY